Chemomab Therapeutics (CMMB) Research & Development (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Research & Development data on file, last reported at $1.1 million in Q4 2025.

• For the quarter ending Q4 2025, Research & Development fell 54.67% year-over-year to $1.1 million; the trailing twelve-month figure through Dec 2025 stood at $5.8 million (down 48.5% YoY), and the FY2025 full-year result was $5.8 million, down 48.5% from the prior year.
• Research & Development for Q4 2025 stood at $1.1 million, up from $960000.0 in the prior quarter.
• Across five years, Research & Development topped out at $6.9 million in Q1 2023 and bottomed at $960000.0 in Q3 2025.
• The 5-year median for Research & Development is $2.8 million (2022), against an average of $2.9 million.
• The widest annual swing landed in 2022, when Research & Development soared 264.69%; it then sank 66.15% in 2025.
• A 5-year view of Research & Development shows it stood at $2.4 million in 2021, then soared by 147.38% to $5.9 million in 2022, then slumped by 47.46% to $3.1 million in 2023, then retreated by 22.15% to $2.4 million in 2024, then plunged by 54.67% to $1.1 million in 2025.
• The last three Research & Development figures came in at $1.1 million (Q4 2025), $960000.0 (Q3 2025), and $1.3 million (Q2 2025), per Business Quant data.

Peer Comparison